Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: Initial response and relationship to multidrug resistance gene 1-Reference-Cited by-同舟云学术

Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: Initial response and relationship to multidrug resistance gene 1

Published:1994 Issue:4 Volume:22 Page:244-249
ISSN:0098-1532
Container-title:Medical and Pediatric Oncology
language:en
Short-container-title:Med. Pediatr. Oncol.

Author:

Wells Robert J.,Odom Lorrie F.,Gold Stuart H.,Feusner James,Krill Carl E.,Waldron Peter,Moulton Thomas A.,Knoppell Eva,White Michael L,Cairo Mitchell S.

Publisher

Wiley

Subject

Cancer Research,Oncology,Pediatrics, Perinatology, and Child Health

Reference38 articles.

1. Biologic Characteristics and Treatment of Acute Nonlymphocytic Leukemia in Children: Report of the ANLL Strategy Group of the Childrens Cancer Study Group

2. : Acute lymphoblastic leukemia. In (eds): “Principles and Practice of Pediatric Oncology.” Philadelphia: JB Lippincott, 1989, pp. 323–366.

3. “Novantrone, Mitoxantrone Hydrochloride for Injection.” (1988) American Cyanamide Co. p. 1.

4. Interactions of antitumor drugs with natural DNA: proton NMR study of binding mode and kinetics

5. Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ATP-Binding Cassette transporters' gene expression in pediatric patients with acute leukemia; a comprehensive analysis of published reports through PubMed search engine;Cellular and Molecular Biology;2019-02-28

2. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma;Pediatric Blood & Cancer;2013-12-19

3. Relapsed and Refractory Pediatric Acute Myeloid Leukemia: Current and Emerging Treatments;Pediatric Drugs;2013-10-25

4. MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis;Biomarkers;2013-06-27

5. A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen;Biology of Blood and Marrow Transplantation;2012-02